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I. INTRODUCTION 
Liver transplantation was recognized in 1983 by a National Institutes of Health 
Consensus Conference as an acceptable therapy for the treatment of end-stage 
liver disease [1]. Currently, pediatric and adult I-year survival after liver trans-
plantation at the University of Pittsburgh are 77 and 64%. Nevertheless, the com-
plications, often requiring reoperation, remain significant. Patients undergoing 
liver transplantation are usually chronically ill and severely debilitated. The stress 
of difficult surgery, which lasts 6-24 hr, must be withstood, followed by the addi-
tional demands of immunosuppressive therapy. 
Many of the complications, such as gastrointestinal bleeding, are common to 
all stressed surgical patients, and many of the infectious complications, such as 
Pneumocystis carinii and Legionella pneumonia, are seen in other immunosup-
pressed patients. In this chapter discussion is limited to complications with a 
special relevance to transplantation of the liver. Each complication is presented 
with an illustrative case report. 
*Present affiliation: University of California San Diego Medical Center, San Diego, Cali-
fornia. 
tPresentaffiliation: Catholic University of Leuven Medical School, Leuven, Belgium. 
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II. PRIMARY GRAFT FAILURE 
As the demand for liver transplantation has increased exponentially in the last 
several years, we have been forced at the University of Pittsburgh to reassess cri-
teria for donor selection. As criteria are liberalized, donor utilization is expanded. 
We have become increasingly dependent upon both the clinical judgment and sur-
gical expertise of the donor surgical team. Primary failure of the donor liver to 
function promptly in the recipient creates a crisis with very high mortality. Al-
though many injured donor livers can and do recover, approximately 5% of the 
livers retrieved fail to function well enough to sustain the recipient. Only urgent 
retransplantation can save the patient faced with this predicament. Between 
March 1, 1980, and December 31, 1984, 83 liver retransplants were performed. 
Primary graft failure was the indication for retransplantation in 15 (18.3%) of 
these cases and carried a mortality of 87%. This is stark contrast to rejection, 
the most frequent indication for retransplantation (49 cases, 59.8%), for which 
mortality was 49%. 
Case History 
A 7 -month-old white male with biliary atresia had undergone a laparotomy and 
liver biopsy at 1 month of age. No biliary reconstruction was done. He recovered 
from operation but developed progressive jaundice and gastrointestinal hemor-
rhage. Esophageal varices were seen by endoscopy. At the time of transplanta-
tion, his bilirubin was 31.2 mg/dL, prothrombin time 18.1 sec (control, 11.7), 
albumin 3.0 g per 100 mL, and his weight 7.8 kg. 
The transplant was difficult, but the operation went according to plan. The 
portal vein and hepatic artery were reconstructed in routine primary fashion; the 
biliary tract reconstruction was our preferred technique of Roux-en-Y choledo-
chojejunostomy. 
Postoperatively, the patient woke up but remained agitated. His initial pro-
thrombin time was 14.5 sec. However, this rapidly deteriorated to 27.5 sec with-
in 36 hr of surgery despite replacement of clotting factors. On postoperative day 
2 the patient became hypoglycemic and required a constant infusion of 25% dex-
trose to maintain acceptable serum glucose levels. A sonogram confirmed patency 
of the hepatic artery and portal vein. By postoperative day 3 the patient had 
lapsed into coma. Computed tomographic (CT) scan of the head was unremark-
able. Urine output was still good, and serum creatinine remained between 0.2 and 
0.6 mg per 100 mL. 
On postoperative day 4 the patient was completely unresponsive with absent 
spontaneous respirations and absent reflexes. Blood cultures grew Pseudomonas 
aernginosa. The patient arrested and died on postoperative day 6. 
The liver function profile was consistent with severe ischemic injury to the 
graft. SGOT peaked at 7763 IU and SGPT at 3085 IU. Bilirubin rose from 11.6 
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mg/dL on the first day to 34.6 mg/dL on the day of death. The patient was 
kept on urgent status for retransplantation during the entire postoperative course, 
but a suitable donor could not be found in time. 
The postoperative course of this patient illustrates most of the features of pri-
mary graft failure. The most sensitive indicator of early liver function is pro-
thrombin time (PT). PT frequently remains elevated during the first 1-3 days 
after transplantation but usually is below 18 sec within 24-36 hr of surgery. 
When the PT remains above 20 sec and fails to improve with clotting factor re-
placement (fresh-frozen plasma, calcium, and cryoprecipitate), primary graft fail-
ure should be suspected. The most likely alternative diagnosis in this setting, es-
pecially in small children, is hepatic artery thrombosis. If Doppler ultrasound can-
not detect hepatic artery pulsations, an arteriogram is indicated. 
Hypoglycemia is uncommon after transplantation and is an ominous sign of 
diffuse hepatocellular dysfunction. Adult patients with primary graft failure may 
wake up after surgery and be promptly extubated, but they too will slip into 
hepatic coma. Brain death tends to occur later than in children. Children with 
severely compromised hepatic grafts often do not wake up after surgery. 
Hepatic transaminases usually peak on postoperative day 2 or 3. Grafts with 
peak SGOT and SGPT in the range 2000-4000 IU are not uncommon and usual-
ly recover. Even grafts with higher peak transaminase levels have recovered, but 
enzyme elevations in the 5000-10,000 range are worrisome. In every case, the 
liver function profile can only be interpreted in the context of the overall clinical 
condition of the patient and does not by itself reliably predict outcome except in 
extreme cases. 
Hepatorenal failure is common with primary graft injury and is a poor prog-
nostic sign. However, it is almost always reversible with retransplantation. 
The ischemic liver is an excellent culture medium, and sepsis is a frequent 
complication of primary graft failure, usually with gram-negative organisms typi-
cal of biliary tract flora. In patients who survive long enough to be retransplanted, 
sepsis is the most common cause of death. 
Assessment of donors remains an imprefect science. The history of the donor, 
including cause of brain death, the number and length of ischemic episodes, the 
amount, type, and length of pressor support, and the clinical liver profile, are all 
important to varying degrees. Transient elevations of bilirubin or transaminases 
are acceptable if significant improvement has been demonstrated. 
An important aspect of donor evaluation is the assessment of the graft by the 
donor surgeon at the time of donor hepatectomy. A discolored, congested, hard 
liver is perhaps the most ominous finding. If the appearance of the liver does not 
improve with volume unloading, the graft should probably not be taken. Precool-
ing by infusion of fluid in the portal vein should be minimized in patients with 
congested livers to reduce the risk of perfusion injury. 
The treatment of primary graft failure is retransplantation. The usual medical 
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measures for the management of acute liver failure are applied while the search 
for a graft is made. 
III. VENOVENOUS BYPASS WITHOUT SYSTEMIC HEPARINIZATION 
Despite the extensive experience with the liver transplant operation in the 17 
years before the introduction of cyc1osporine therapy, only a few important 
technical improvements have contributed to improved patient survival. Even 
during the first 3 years in which cyc1osporine was used, mortality related to a 
difficult intraoperative course remained a disturbing problem. In 1980, 30-day 
surgical mortality was 19.2%, and in 1982 it was 27.4%. In 1983 it declined to 
15.8% and for 1984 fell to the lowest level, 8.9%. The routine use of a pump-
driven yenovenous bypass system since 1983 has been the major development 
contributing to this improvement in survival [2] . 
For the most part, the technical difficulties have centered around the anhepat-
ic phase, with its associated splanchnic congestion, cardiodynamic instability, 
renal vein hypertension, hemorrhage, and limited exposure and time. The de-
velopment of a pump-driven venovenous bypass was stimulated by the need to 
overcome these problems. 
The acute interruption of portal and systemic venous return required in liver 
transplantation creates several problems: 
1. A sudden fall in central venous return and pulmonary artery wedge pres-
sure resulting in a decrease in ventricular preload and cardiac output and 
an increase in systemic vascular resistance (afterload) 
2. Severe venous hypertension in the obstructed portal and systemic venous 
beds with edema and congestion of the kidneys, intestines, and pancreas 
and exacerbation of hemorrhage from thin-walled high-pressure venous 
collaterals 
3. Sudden return of stagnant blood rich in acid and potassium from the ob-
structed venous beds into the systemic circulation upon revascularization 
of the hepatic graft 
Passive shunts were employed during the first human trials of liver transplanta-
tion but were abandoned because of pulmonary emboli and patient mortality. In 
1982, in collaboration with the cardiac surgery division, trials began of a venous 
bypass using conventional systemic heparinization but the bleeding complications 
were unacceptable. Development of the pump-driven nonheparin bypass system 
was then undertaken, and the success of this effort has recently been reported by 
this institution [2,3]. The bypass is used routinely in adult patients and in older 
children. Application in small children has been hindered by lack of a suitable 
site for venous return to the patient and the low flow rates attainable. 
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The technique of bypass has been discussed elsewhere and is beyond the scope 
of this discussion [2-4]. The advantages of the system include 
1. Maintenance of mean arterial pressure, central venous pressure, and pulmo-
nary artery wedge pressure at prehepatectomy levels with a decreased inci-
dence of cardiac arrhythmias, hypotension, and organ hypoperfusion 
2. Elimination of the need for excessive volume preloading of the patient and 
therefore less risk of pulmonary edema at the time of liver revascularization 
3. Protection of the kidneys from renal venous hypertension and hypoperfu-
sion with a significant reduction in postoperative renal dysfunction 
4. A significant decrease in the mean operative and early postoperative blood 
replacement requirements 
5. A significant improvement in P~-day patient survival 
The routine use of venovenous bypass has converted the anhepatic phase of 
liver transplantation into a controlled, calm procedure, but it is not without inher-
ent problems. A major risk of using a nonheparinized bypass system is the devel-
opment of thrombus in the bypass tubing and in the cannulated veins, which could 
result in pulmonary embolization. Although this has been an infrequent occur-
rence, both pulmonary emboli and deep venous thrombosis have been documented 
and have been a rare cause of patient death. The case report below is one example. 
One effort to alleviate this problem has led to the development of a commercially 
produced, heparin-bonded single-circuit polyvinyl chloride tubing system that in-
corporates the bypass pump head. The system is primed before use with Ringer's 
lactate containing dilute (1: 1000) heparin. In patients with small veins, smaller 
caliber chest tubes can be adapted to the ends of the tubing to facilitate cannula-
tion. 
During bypass, the rotation of the centrifugal blood pump is kept to the mini-
mum revolutions per minute required to maintain an acceptable flow of at least 
1000 mL/min. Usually flows of 2-3 L/min are obtained. In children, using 
heparin-bonded and dilute heparin-primed tubing, flows down to 500 mL/min 
may be acceptable. Maintenance of adequate flow reduces the risk of thrombus 
formation. The use of one-piece tubing systems, careful priming of the system 
to eliminate air bubbles, and moderate pump speed minimizes the risk of introduc-
ing air into the bypass. 
Certain patients may present special risks for use of the venovenous bypass. 
One patient with polycystic disease of the liver who was transplanted to relieve 
massive hepatomegaly and inferior vena cava obstruction suffered a fatal pulmo-
nary embolus soon after initiating bypass. Two patients with Budd-Chiari syn-
drome had attempts at thrombectomy of the clotted portal vein and vena cava 
followed by establishment of bypass. Flows in the circuit were critically low with 
great risk of thrombus formation in the bypass circuit. Bypass was abandoned in 
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both patients without further incidence. Such conditions, with preexisting 
thrombus in the venous beds, are contraindications to the use of bypass. 
Wound hematomas, seromas, or lymphoceles in the access wounds in the 
groin or axilla have occurred in approximately 25% of patients. Usually these 
are mild, self-limited problems, but surgical exploration and drainage are occa-
sionally required. There has been one significant brachial plexus injury in a child. 
Meticulous dissection and gentle handling of neural tissues are essential to mini-
mize these complications. 
The following case report illustrates the risk of thrombotic complications asso· 
ciated with the use of venovenous bypass. 
Case Report 
A 30-year-old female was admitted in fulminant hepatic failure from B virus hepa-
titis. She failed to improve after 12 hr of vigorous medical therapy. An appro-
priate liver donor was found within 24 hr. At surgery, the hilum and ligaments 
of the liver were dissected without incident. The patient was placed on veno-
venous bypass. Heparin-bonded Gott shunts were used to cannulate the vena 
cava via the saphenofemoral system, the axillary vein, and the portal vein. By-
pass flow was 3 L/min. During anastomosis of the suprahepatic vena cava, there 
was a sudden rise in pulmonary artery pressure followed by a cardiac arrest. All 
efforts at resuscitation failed, and the patient expired on the operating table. The 
right atrium was opened and approximately 100 mL of soft clot was found. 
Thrombus was also found in the bypass tubing. 
IV. GRAFT-VERSUS-HOST DISEASE 
Whenever possible, liver transplantation is carried out between ABO blood group 
matched donors and recipients. In kidney transplantation, ABO matching is essen-
tial, since the presence of ABO isoagglutinating antibodies against a renal graft 
almost always result in hyperacute rejection of the graft. The liver, however, is 
privileged, and hyperacute rejection has not been observed when liver transplanta-
tion is performed between ABO-mismatched donor and recipients. The use of 
ABO-mismatched grafts, such as transplantation of a group 0 liver to an non-
group 0 recipient or a group A or B liver to a AB recipient, is done frequently 
for patients in urgent need of transplantation and for small children, for whom 
the supply of available donors is especially limited. 
The liver graft, a reticuloendothelial organ, can produce isoagglutinating anti-
bodies against the ABO blood determinants of the recipient. A large number of 
lymphocytes accompany the liver from donor to recipient in both the lymphatics 
of the liver and the lymph nodes in the hepatic hilum. Therefore, the graft con-
tains a significant number of B lymphocytes with the potential to produce anti-
ABO group determinant antibodies. Ramsey et al. [5] were able to detect such 
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ABO antibodies in 27.6% of recipients of ABO-mismatched livers. No such anti-
bodies were found in 180 recipients of ABO-matched transplants. In five of the 
eight patients with detectable antibodies, there was clinical evidence of signifi-
cant hemolysis occurring well after the period of perioperative transfusion re-
quirement. Antirecipient ABO antibodies were first detected 8-16 days after 
transplantation and were last seen 11-41 days after surgery. Hemolysis, when 
present, was seen between 5 and 8 days after surgery and lasted 7-19 days. 
The hemolytic graft-versus-host reaction that occurs with transplantation of 
an ABO-mismatched graft is usually self-limited and treatment with immuno-
suppression is already in place. The following case report illustrates the clinical 
course. 
Case Report 
An ll-year-old male, blood group A, with type II homozygous hypercholesterol-
emia was admitted for hepatic transplantation to reverse his life-threatening en-
zyme deficiency. His disease was manifested by cutaneous xanthomas, atypical 
angina pectoris with demonstrable coronary artery stenosis, and two right parie-
tal cerebrovascular accidents. The best available donor, blood group 0, had a 
larger liver requiring a left lateral segmentectomy at transplantation. 
The patient made a prompt recovery from surgery but developed enzyme and 
electrocardiographic findings of acute myocardial infarction. This resulted in 
mild, transient pulmonary edema. The patient improved, but a drop in hemato-
crit from 32 to 18% occurred on postoperative day 10 with no evidence of exter-
nal bleeding. Direct Coombs test was positive, and Circulating anti-A blood 
group antibody was detectable. The patient was treated with a 2-unit packed 
red blood cell transfusion and an intravenous bolus of 500 mg methylpredniso-
lone. He developed a severe thrombocytopenia (platelet count 4000 mm 3 ) 
and epistaxis 14 days after transplantation. He received another bolus of 500 
mg methylprednisolone followed by a 5-day burst of steroids starting at 200 
mg methylprednisolone on the first day and tapering by 40 mg/day until reach-
ing a maintenance dose of 20 mg/ day. Azathioprine, 50 mg/day, was added. The 
platelet count remained below 10,000 mm 3 for the next 6 days, and a splenec-
tomy was performed. Over the next 10 days the platelet count slowly recovered. 
The self-limited hemolytic anemia experienced by this patient was typical of 
the findings in the graft-versus-host response seen with ABO-mismatched donor 
and recipient. The thrombocytopenia is unusual but could also have been re-
lated to antibody coating and damage to platelets, which were then removed from 
the circulation by the spleen and possibly also by the liver. This case is excep-
tional in that previously we have not had to perform a splenectomy in patients 
with ABO-mismatched grafts. 
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V. VASCULAR THROMBOSIS 
Technical complications remain an important cause of morbidity and mortality 
after liver transplantation. Thrombosis of the hepatic artery is one of the most 
common and most serious complications. In a recent review of 244 patients 
who received 309 liver transplants at the University of Colorado and the Univer-
sity of Pittsburgh from March 1980 to June 1984,22 cases (7.1 %) of hepatic 
artery thrombosis were identified [6]. Of these, 14 cases occurred in children 
(11.8%) and 6 in adults (3.4%). Mortality was 37.5% in children and 50% in 
adults. A total of 66 liver retransplants were performed during this period: 13 
(19.7%) were for hepatic artery thrombosis; 9 patients (62.9%) survived. Only 
27.3% of the patients not retransplanted survived. A specific anatomic cause of 
thrombosis was identified in only 3 cases: an intimal dissection of the hepatic 
artery in 2 and medial necrosis and intramural hemorrhage of the celiac axis in 1. 
The clinical presentation of hepatic artery thrombosis usually follows one of 
three patterns: 
1. Fulminant hepatic necrosis (8 patients) with frank hepatic gangrene char-
acterized by a rapid rise in serum transaminase levels and rapid clinical de-
terioration between 9 and 33 (mean 16.4) days after transplantation (Fig. 1) 
2. Delayed biliary leak (7 grafts in 6 patients) at 7-65 (mean 29.0) days after 
transplantation from ischemic necrosis of the bile duct manifested by sub-
hepatic fluid collections, drainage of bile through abdominal drains, frank 
bile peritonitis, bacteremia, and changes in the clinical liver profile (bili-
rubin and transaminases) often similar to those seen with graft rejection 
3. Relapsing bacteremia in 7 cases characterized by an indolent clinical course 
presenting 1545 (mean 26.7) days after transplantation, usually with only 
minor abnormalities in the liver function profile 
Case Report 
A seriously ill 4-year-old male with £\(1 -antitrypsin deficiency received a liver trans-
plant with a double hepatic arterial supply. The left hepatic artery arose from the 
celiac axis and the right hepatic artery from the superior mesenteric artery. Re-
construction required the use of donor throack aorta left attached to the celiac 
and superior mesenteric arteries and implanted into the right common iliac artery. 
The patient had Klebsiella septicemia with moderate elevations of liver function 
studies 4 weeks after surgery. No obvious source of sepsis was found, but the pa-
tient responded well to antibiotic therapy. The patient had a second episode of 
Klebsiella septicemia 1 week later. A CT scan of the abdomen suggested the pres-
ence of thrombus in the thoracic aortic conduit, and an arteriogram was obtained 
that confirmed arterial thrombosis. Initially the patient was managed conserva-
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Figure 1 Complications of hepatic artery thrombosis. Selective celiac angiog-
raphy demonstrating hepatic artery thrombosis (arrow) and resulting in air in the 
liver. 
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tively since he remained clinically stable. However , when antibiotics were dis-
continued he again became septic and developed gastrointestinal bleeding. He 
was retransplanted at 53 days. The bile ducts in the first graft were impacted 
with inspissated bile and old blood clots. Disimpaction of this material resulted 
in vigorous hemorrhage from a portobiliary fistula. The patient died 15 days 
after retransplantation of hemorrhage caused by rupture of a mycotic aneurysm 
at the suture line between the new aortic conduit and the native aorta. 
Hepatic artery thrombosis must be considered in all patients presenting with 
fever and a positive gram-negative blood culture after transplantation. If hepatic 
arterial pulsations cannot be detected with the Doppler ultrasound, arteriography 
is indicated (Figs. ] and 2). Laparotomy is a potentially dangerous diagnostic 
maneuver. Manipulation of the devascularized liver may result in severe hemor-
rhage and septicemia. Evaluation of the hepatic artery is sometimes difficult since 
an artery with a palpable pulse may be thrombosed at a more distal level or a 
transmitted pulse in an occluded vessel may be misinterpreted as a sign of vessel 
patency. 
Although patients with arterial thrombosis may have a fulminant clinical 
course, many patients have a subtle and indolent course. The principal injury 
of hepatic arterial thrombosis is ischemic necrosis of intrahepatic or extrahepatic 
bile ducts. If the extrahepatic ducts are involved, extrahepatic bile abscess or 
frank bile peritonitis occurs, which requires laparotomy for drainage and even-
tualliver replacement. If the intrahepatic ducts are involved, hepatic abscess is 
common. In milder cases, late biliary strictures may develop. CT scans are use-
ful in detecting bile collections inside or outside the liver (Fig. 3a). Percutaneous 
or T-tube cholangiography may be necessary to define the biliary tract anatomy 
(Fig. 3b). Percutaneous transhepatic catheter manipulation can drain intrahepatic 
collections and permit dilatation of strictures. In the occasional case this may be 
sufficient to permit healing and avoid the need for retransplantation. 
Hepatic artery thrombosis must be differentiated from primary graft failure 
and primary biliary tract technical complications. Herpetic hepatitis, a rare com-
plication, can attack the biliary system and result in disruption of the bile duct. 
Bile duct stricture, intra-abdominal abscess, or other undetected sources of per-
sistent infection must also be excluded. 
Most patients with hepatic arterial thrombosis require retransplantation. Chil-
dren and some young adults appear to tolerate hepatic arterial thrombosis more 
readily than older patients and are more likely to present with an indolent 
course. Younger patients are better able to develop hepa topedal arterial colla ter-
als (Fig. 2). Although a limited number of patients have been initially managed 
successfully with antibiotics and , as indicated, percutaneous transhepatic manipu-
lation, the long-term durability of such management remains to be established. 
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Figure 2 Selective superior mesenteric arteriography showing the extensive collat-
eral circulation that has developed in the right upper quadrant following thrombo-
sis of the hepatic graft artery. 
Portal vein thrombosis (Fig. 4) is much less common after liver transplantation 
and has occurred in only 6 of 313 recipients. The majority of cases occurred in 
patients with previous surgery for portal hypertension, such as portacaval shunting 
or splenectomy. Other potential causes include technical mistakes, such as stric-
ture, misalignment , or excessive length (Fig . 5), hypercoagulable states, and throm-
bus formation resulting from the presence of the venovenous bypass cannula. 
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(A) 
Figure 3 Biliary tract complications after hepatic arterial thrombosis (same 
patient as Fig. 2). (A) CT scan demonstrating a single hypodense zone (arrow) 
in the transplan ted liver. (B) Percll taneOllS transhepatic cholangiogram demon-
strating a significant biloma (arrow) that corresponds to the findings on the CT 
scan. 
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(8) 
Figure 3 (continued) 
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Figure 4 Venous phase of a selective superior mesenteric arteriogram demon-
strating thrombosis of the portal vein (arrow) and formation of secondary venous 
collaterals. 
Clinical presentation of portal vein thrombosis is variable. It may present 
acutely with hepatic failure, intestinal swelling, and massive ascites or, more 
often, with chronic ascites and variceal hemorrhage. The diagnosis is confirmed 
by arteriography and has been made at laparotomy. Treatment is retransplanta-
tion or, when feasible, conservative management of portal hypertension . 
Other vascular complications that may have a similar clinical presentation and 
require retransplantation are mycotic aneurysms and pseudoaneurysms. In small 
children and in patients with significant disease of the native hepatic artery, it is 
often necessary to use donor aortic or iliac arterial segmen ts as grafts for rearteri-
alization of the liver. These grafts are usually sewn into the recipient infrarenal 
aorta and tunneled under the pancreas to reach the hepatic hilum. A short tunnel 
can be made above the left renal vein and superior mesenteric artery and under 
Figure 5 Portal vein thrombosis resulting from technical error. (a) Stenosis of the portal vein anastomosis (arrow) 
diagnosed at transhepatic portography. (b) Operative venogram through a mesenteric vein demonstrates complete 
portal obstruction (arrow). (c) Management of this problem consisted of resection of the stenosis, thrombectomy, 
and reanastomosis (arrow). 
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(A) 
Figure 6 Pseudoaneurysm (arrows) of an aortic graft in a pediatric liver trans-
plant recipient demonstrated by both CT scan (A) and aortography (B) . 
the neck of the pancreas, or a longer tunnel can be made crossing over the in-
ferior vena cava and under the superior mesenteric artery, head of the pancreas, 
and duodenum. The anastomosis between the donor arterial conduit and the 
recipient aorta has been the most frequent site of pseudoaneurysm or mycotic 
aneurysm formation (Fig. 6) . Ultrasound and CT scanning have been helpful 
in making the diagnosis. 
VI. BILIARY TRACT COMPLICATIONS 
The two principal technical advances in liver transplantation in recent years have 
been the development of a reliable, effective venovenous bypass technique and 
standardization of the techniques for biliary reconstruction. Direct duct-to-duct 
(choledochocholedochostomy) over aT-tube stent in adults is the preferred 
method of reconstruction when possible. In children with biliary atresia and 
other patients with disease rendering the recipient bile duct unsuitable for direct 
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(B) 
Figure 6 (continued) 
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reconstruction, anastomosis of the donor bile duct to Roux-en-Y limb of jejunum 
(choledochojejunostomy) is the reconstruction of choice . These reconstructions 
are now successful in over 90% of cases . 
In 313 patients between March I, 1980, and December 31, 1984, biliary tract 
complications occurred in 52 patients [7] . Of these patients, 5 (9 .6%) died as a 
direct result of the complication . Prior to this period, the incidence of biliary 
tract complications was even higher. It had been thought that a deficient blood 
supply of the graft duct system was responsible for the high incidence of compli-
cations, but, in fact, the majority of problems were probably the result of inappro-
priate surgical techniques, such as choledochoduodenostomy, and the failure to 
diagnose complications promptly. With the advent of cyclosporine-steroid immu-
nosuppression in 1980, frequent use of postoperative cholangiography, standard-
ization of choledochocholedochostomy and Roux-en-Y choledochojejunostomy, 
and prompt operative intervention for complications, the incidence of complica-
tions and morbidity and mortality have decreased markedly. 
It has already been emphasized that primary biliary tract complications must 
be differentiated from those secondary to arterial insufficiency. Other less com-
mon and unusual biliary tract complications include bile cast syndrome, trans-
plantation of a traumatized liver, and unexplained changes in the peripheral intra-
hepatic bile ducts not related to the biliary anastomosis. 
Case Report 
A 34-year-old female received a liver transplant for chronic aggressive hepatitis. 
The operation went without incident, and a direct duct-to-duct biliary reconstruc-
tion over a T tube was performed. Completion and postoperative cholangiography 
demonstrated a normal biliary tree and patent leak-free anastomosis. The early 
postoperative course was complicated by pneumonia and several episodes of 
acute rejection treated with corticosteroids. 
A cholangiogram performed on postoperative day 53 showed a stricture at the 
confluence of the hepatic ducts of the graft and dislocation of one T -tube limb 
out of the biliary tract. The tube was replaced percutaneously by a straight tube 
stent. The stricture was treated by seven percutaneous balloon dilatations. The 
stricture was dilated to 12 mm, resulting in a patent duct with no detectable pres-
sure gradient across the site of the stricture. 
The patient was again hospitalized 18 months later with an abnormal liver 
function profile. A liver biopsy showed moderate allograft rejection. Percutane-
ous transhepatic cholangiography and ERCP demonstrated recurrence of the stric-
ture. Percutaneous balloon dilatation was unsuccessful, and the patient was re-
constructed with a Rou x-en-Y hepaticojejunostomy. Histology showed only 
mild fibrosis of the duct. The patient made an uneventful recovery . U1trasound 
of the liver prior to hospital discharge showed no dilatation of the biliary tree. 
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This case demonstrates several important aspects of biliary tract reconstruc-
tion in liver transplantation (Fig. 7). First, the differential diagnosis between 
rejection and biliary tract complications can be difficult. Second, T tubes and 
stents may dislocate or migrate out of proper position predisposing to stricture. 
Third, biliary tract obstruction need not involve the anastomosis even in the 
absence of ischemic injury to the graft ductal system. Fourth, percutaneous 
transhepatic dilatation is only an interim method of management. Definitive 
management usually requires resection of the obstruction and mucosa-to-mucosa 
repair of the bile duct to a Roux-en-Y jejunal loop. 
The biliary tract reconstruction is no longer the "Achilles heel" of liver trans-
plantation. The use of standard reconstructive techniques, appropriate postoper-
ative investigation, and aggressive intervention when a complication is identified 
can minimize morbidity and mortality and save most grafts. 
VII. VIRAL HEPATITIS 
Infection still accounts for much of the morbidity and mortality after liver trans-
plantation. The differential diagnosis of liver dysfunction after transplantation 
is complicated by the difficulty of distinguishing rejection from postoperative 
viral hepatitis. Cytomegalovirus (CMV) infection of the liver is a particularly 
troublesome and still frequent occurrence. Between March 1980 and September 
1985 we have identified 17 patients with pathologically proven CMV hepatitis 
after liver transplantation. 
CMV hepatitis tends to occur relatively late after transpIantation (15-132 days ; 
mean, 44 days). It is characterized by elevation of bilirubin and transaminases 
with a prolonged clinical course of spiking temperatures (ranging 5-68 days in 
15 of the 17 patients). Since the management of viral infection and rejection is 
radical1y different, the establishment of the correct diagnosis is essential. Per-
cutaneous liver biopsy is the method of choice and is performed frequently on 
our service. Prior to our liberal use of biopsy, three patients had .liver retrans-
plantation for an incorrect diagnosis of rejection based only on liver function 
abnormalities . AIl three patients had been overimmunosuppressed because of 
the mistaken diagnosis. AIl three patients ultimately died. At autopsy CMV 
hepatitis, not rejection, was found . 
More striking evidence of the need for liver biopsy is found in further evalu-
ation of the 17 confirmed cases of CMV hepatitis in our series. Of the first 8 
patients,S were diagnosed at the time of retransplantation. The next 9 patients 
were all diagnosed by percutaneous biopsy . Only 4 of 12 patients diagnosed by 
biopsy have died compared with 4 of the 5 patients diagnosed at reoperation. 
CMV infection is diagnosed by serological changes and/or isolation of the 
virus. Liver biopsy may show the typical inclusion bodies in the hepatocytes, 
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(A) 
Figure 7 Bile duct stricture after liver transplantation. (A) Operative cholangio-
gram (left) demonstrating normal biliary tree after the initial reconstruction . 
Cholangiography (right) demonstrating stricture of the donor common hepatic 
duct. (B) Cholangiogram showing a dislodged T tube lying outside the biliary 
tree, which was subsequently replaced with a straight tube stent. (C) The dis-
lodged T tube has been replaced with a straight tube stent passed up toward 
the hepatic duct bifurcation. (D) Cholangiography showing resolution of the 
stricture after repetitive percutaneous transhepatic balloon dilatations. No pres-
sure gradient was detectable across the stricture site. (E) Cholangiography show-
ing recurrence of the stricture 2 years later subsequently treated by conversion 
of the choledochocholedochostomy to a Roux-en-Y choledochojejunostomy. 
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Figure 7 (continued) 
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Figure 7 (continued) 
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Figure 7 (continued) 
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but biopsy material should always be cultured since isolation of virus is the best 
way to establish the diagnosis . CMV infection can occur primarily, as estab-
lished by seroconversion, or by reactivation of prior infection, as documented 
by a fourfold or greater rise in antibody titer. Reactivation is promoted by im-
munosuppression. Primary infection in the transplant patient can originate 
from many sources, including the graft itself and blood products. Greater than 
35% of the U.S. population is serologically positive for CMV and thus the virus 
is frequently transmitted from donor to recipient. Of the 17 cases we reviewed, 
8 patients had primary infection and 1 had definite and 5 had probable reactiva-
tion of infection. In 3 cases, insufficient serum samples were available to make 
a determination. 
The finding of primary infection in 8 of 14 (57%) patients with CMV hepatitis 
is higher than one would expect and suggests that patients with primary infec-
tion are more at risk of developing significant hepatitis [8]. It is well known 
that primary CMV infections tend to be more symptomatic and result in higher 
morbidity and mortality in immunocompromised patients, such as kidney trans-
plant patients [7]. It is important to note, however, that in the group of 17 
patients with CMV hepatitis we recently reviewed, we found no difference in 
clinical prognosis between primary infection or reactivated infection. 
Most CMV infections are self-limited if immunosuppression is managed with 
restraint. It is also worth noting that CMV infection is by itself immunosuppres-
sive . Full maintenance of immunosuppressive agents in the face of CMV infec-
tion may easily result in dangerous overimmunosuppression and increase suscep-
tibility to other opportunistic infections. 
Once the diagnosis of CMV hepatitis is established, our management strategy 
includes reduction of cyclosporine to achieve moderate blood levels (400-500 
ngJmL by whole-blood RIA) and reduction of maintenance steroids from 20 
to 10 mg/day or less. As the disease resolves, cyclosporine is increased to main-
tain blood levels in the usual therapeutic range (800-1000 ng/mL). 
The management of the occasional patient with both rejection and CMV 
hepatitis is difficult. We often reduce the daily maintenance dose of steroids but 
supplement therapy with boluses of 0.5-1.0 g of methylprednisolone or hydro-
cortisone every 4-5 days. CMV hepatitis may worsen after therapy for rejec-
tion, requiring judicious lowering of immunosuppression. Finally, in some 
cases , only retransplantation can save the patient. 
Hepatitis B virus, adenovirus, and herpesvirus are other less common offen-
ders . Hepatitis B is also often self-limited and managed by conservative immu-
nosuppressive therapy. Herpes and adenovirus hepatitis are rare but often omi-
nous and severe. 
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Case Report 
A 23-year-old male underwent an uneventful orthotopic liver transplant in De-
cember 1983 for end-stage sclerosing cholangitis. He did well postoperatively 
until about day 16, when he developed significant elevations in bilirubin and 
hepatic transaminases. His temperature reached 39°C, and fever lasted for 6 
days. A cholangiogram and an arteriogram were normal. Liver biopsy was not 
performed. He was treated for rejection with steroids and antilymphocyte globu-
lin without significant improvement in liver function. 
The patient suddenly deteriorated with disorientation, hypoxia, and bilateral 
pulmonary infiltrates requiring intubation and high-pressure ventilatory support. 
Retransplantation was performed, but the patient died 7 days later. Pathological 
examination of the first liver graft showed severe cytomegalovirus hepatitis with-
out evidence of rejection. CMV was also identified in the spleen, which had also 
been removed at surgery. CMV was isolated in urine and from buffy coat blood. 
In addition, Clostridium difficile was isolated from the spleen and Staphylococ-
cus aureus and Enterobacter were isolated from blood. 
This case demonstrates the severe penalty for treating viral hepatitis as rejec-
tion. A liver biopsy can be especially helpful in this situation and prevent inap-
propriate immunosuppressive treatment. 
VIII. CONCLUSION 
Just a few years ago, the patient with end-stage liver disease had little to hope 
for. Liver transplantation was still an experimental procedure with a high mor-
bidity and mortality. Today, the surgical technique, though still demanding, 
has become standardized and operative mortality is below 10%. Cyclosporine 
and monoclonal antibody therapy have made rejection more manageable. 
Nonetheless, the majority of patients undergoing liver transplantation will 
experience at least one major complication and many will require at least one 
additional operation. Fortunately, our experience in recognizing and managing 
the complications of liver transplantation has also grown in recent years, and 
this also has contributed significantly to the improved survival now being en-
joyed by our patients. 
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